hit counter
Arbutus Biopharma Corporation (ABUS) Stock News Sentiment & Price - Sentifly
ABUS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Arbutus Biopharma Corporation (ABUS)

Canada
Biotechnology
NASDAQ
ABUS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ABUS Latest news
PennyStocks
Positive
5 Short Squeeze Penny Stocks To Watch For November 2021
2021-10-26 11:16

Are these penny stocks ready to short squeeze? The post 5 Short Squeeze Penny Stocks To Watch For November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire
Neutral
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
2021-10-21 07:30

WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021. The schedule for the press release and conference call/webcast are as follows:

PennyStocks
Positive
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
2021-10-10 10:45

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

PennyStocks
Positive
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
2021-10-03 10:45

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire
Neutral
Arbutus to Participate in October Investor Conferences
2021-09-28 07:30

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences:

Zacks Investment Research
Neutral
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
2021-09-27 10:03

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

GlobeNewsWire
Neutral
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
2021-09-21 07:30

WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced the Company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus' Chief Financial Officer.

Pulse2
Positive
ABUS Stock: Why It Increased This Week
2021-09-10 08:10

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased more than 12.5% over the past few trading days. This is why it happened.

Zacks Investment Research
Neutral
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
2021-08-23 09:56

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Seeking Alpha
Neutral
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript
2021-08-05 15:06

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript

Loading more news...